Rasilez has received regulatory approval in China as a treatment of high blood pressure, either alone or in combination with other high blood pressure medicines.

Novartis‘ drug inhibits the activity of renin, an enzyme produced by the kidney that triggers a process that may lead to high blood pressure, the leading preventable cause of death in China.

It provides significant blood pressure reductions lasting at least 24 hours, alone or in combination with other anti-hypertensives.

Rasilez is the trade name for aliskiren, except in the US where it is known as Tekturna, and is approved in over 80 countries.

Around 153 million adults in China suffer from high blood pressure, with the majority of patients not reaching their optimal treatment goal.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData